← Back to federal legislation
H.R. 4434In committee

Cosmetic Supply Chain Transparency Act of 2025

Introduced: Jul 16, 2025

Latest action date: Jul 16, 2025

Latest development

Referred to the House Committee on Energy and Commerce.

Civixly approval

No ratings yet

0 ratings

Not enough ratings yet. Public approval appears at 5+ ratings.

Your view
0 comments
Congress
119th Congress
Introduced
Jul 16, 2025
Recorded roll calls
0

Status detail: The most advanced recorded stage is committee consideration.

Plain-language overview

What this bill does

Cosmetic Supply Chain Transparency Act of 2025

This bill requires the Food and Drug Administration (FDA) to maintain a list of certain chemicals incidentally present in cosmetics, known as nonfunctional constituents, that are harmful to human health or the environment. The bill also imposes certain testing and disclosure requirements on cosmetics brand owners (i.e., entities bringing cosmetics to market) and suppliers of cosmetics, packaging, and ingredients.

For each listed nonfunctional constituent, the FDA must identify the ingredient or cosmetic in which the constituent is known or reasonably expected to be present. The FDA must also (1) accept petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance.

Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request.

Brand owners and other entities in the supply chain of a cosmetic must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request.

The bill also imposes civil penalties for entities that violate this bill's provisions.

Official summary from Congress.gov.

Civixly topics

What this legislation is about

Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.

Official CRS policy area

Health

Committee activity

Committees and subcommittees that received, reviewed, marked up, or reported this legislation.

Amendments

Proposed changes to this measure, with their latest official outcome or action from Congress.gov.

No amendments are listed for this measure.

Checked against Congress.gov Oct 11, 2026.

Action timeline

Newest action first. Action language comes from the official Congress.gov record.

View full action timeline3 actions
  1. Introduced in House

    IntroReferralLibrary of Congress
  2. Introduced in House

    IntroReferralLibrary of Congress
  3. Referred to the House Committee on Energy and Commerce.

    IntroReferralHouse floor actions

Roll-call votes

Recorded House and Senate votes connected to this bill. Your representatives appear first when available.

No connected roll-call votes are currently available for this bill.

Discussion

0 comments across 0 threads

Sign in to join the discussion.Comments are publicly visible.

Loading comments...

Sources: Congress.gov and official House and Senate vote records.

View data freshness details

Base metadata check pending · Civixly summary check pending · Action timeline checked Oct 11, 2026 · Complete sponsorship check pending · Topics checked Oct 11, 2026 · Committees checked Oct 11, 2026 · Status checked Oct 11, 2026 · Related bills checked Oct 11, 2026.